Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd

Bullboard Posts

Comment by Straniuson Nov 15, 2017 3:49am

174 Views

Post# 26965651

RE:Long Revive at Current Levels - A No Brainer

Well that didn't take long. No sooner than after market close, Aurora announced essentially a hostile offer for... wait for it.... CanniMed (link), a cannabis bio-science company, with 38% of CanniMed shareholders locked up.

This is going to create an interesting dynamic now with the other producers looking around the room thinking they don't want to be the last one standing when the music stops. With this deal, there is a cross-hair on the back of every cannabis bio-science company out there. This should provide a nice tailwind for RVV given its ultra-low valuation.

The smart guys in the room are already running comps overnight on the space figuring out who is next. If you are lucky, you may still be able to place your bets before they show up.

~S

Stranius wrote: It's hard to understand how this name is trading with a market cap of $12M when the large growers are on a tear with valuations of several billions of dollars.

If nothing else, at some point someone at one of these large Canadian growers will figure out a name like RVV is a cheap cheap way to acquire a cannabis bio-science company. Given their multi-billion dollar valuation, acquiring someone like an RVV, is a very inexpensive option on the bio-science space rather than developing it themselves and get a leg up on their producer competitors.

What we are seeing now is bumping up against resistance of a slew of disenfranchised shareholders that have become tired of holding this at a loss from pre-May 2017 (everyone that purchased above the pink line in chart below) and those tired of hoping for a run since May 2017 (everyone that purchased below the pink line in chart below).

Once we break through this initial resistance we should see a rerating in the valuation of this name

~S